Hepavue

Over 2 billion people – more than a quarter of the world population – suffer from chronic liver disease. Today, the needle biopsy remains the only diagnostic option. This method is fraught with disadvantages. It is expensive, painful, resource-intensive, samples only a tiny part of the liver and carries a bleeding/mortality risk. As such it is unsuitable for mass screening. This shortcoming - coupled with liver diseases progressing silently - results in 70% of patients going unnoticed until terminal stage (cirrhosis). HepaVue has developed the world’s first virtual liver biopsy which will make liver disease diagnosis affordable, painless, safe and more accessible. Our technology will prevent avoidable cases of liver cancer, transplantations and deaths.